PAX 2: A novel müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma

International Journal of Gynecological Pathology

Volumn 28, Issue 6, 2009, Pages 570-578

  Chivukula, Mamatha ^a   Dabbs, David J ^a   O'Connor, Siobhan ^a   Bhargava, Rohit ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Invasive ductal carcinoma; Metastatic ductal carcinoma; Micropapillary; PAX 2; Serous carcinoma; WT 1

Indexed keywords

POLYCLONAL ANTIBODY; TRANSCRIPTION FACTOR PAX2; TUMOR MARKER; WT1 PROTEIN; PAX2 PROTEIN, HUMAN;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MUELLERIAN DUCT; OVARIAN SEROUS PAPILLARY CARCINOMA; OVARY CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TISSUE SECTION; BIOSYNTHESIS; BREAST TUMOR; CYSTADENOCARCINOMA; DIFFERENTIAL DIAGNOSIS; METABOLISM; OVARY TUMOR; PATHOLOGY;

BREAST NEOPLASMS; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; PAX2 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 73949103285     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3181a76fa2     Document Type: Article

References (26)

1. Luna-Moré S, Gonzalez B, Acedo C, et al. Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma. Pathol Res Pract 1994;190: 668-674
2. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin versus GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007;127:103-113
3. Fritzsche FR, Thomas A, Winzer KJ. Co- expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Histopathology 2007;22:1221-1230
4. Chivukula M, Kapali M. Expression of Wilms tumor gene (WT-1) in Primary Peritoneal Papillary Serous Carcinomas. Modern Pathology 2005; Abstract no. 150. Poster: 94th Annual Meeting of United States and Canadian Academy of Pathology, 2005, San Antonio, TX.
5. Hashi A, Yuminamochi T, Murata S. Wilm's tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 2003;22:374-377
6. Hwang H, Quenneville L, Yaziji H, et al. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol 2004;12:122-126
7. Lee AHS, Paish EC, Marchio C, et al. The expression of Wilms' tumour gene-1 and Ca 125 in invasive micropapillary carcinoma of the breast. Histopathology 2007;51:824-828
8. Moritani S, Ichihara S, Hasegawa M, et al. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Hum Pathol 2008;39:666-671
9. Domfeh AB, Carley AL, Striebel JM, et al. WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes. Mod Pathol 2008;2:1217-1223
10. Bouchard M, Pfeffer P, Busslinger M. Functional equivalence of the transcription factors PAX 2 and PAX 5 in mouse development. Development 2000;127:3703-3713
11. Bouchard M, Souabni A, Mandler M, et al. Nephric lineage specification by PAX 2 and PAX 8. Genes Dev 2002;16: 2958-2970
12. Chi N, Epstein JA. Getting your PAX 2 straight: PAX 2 proteins in development and disease. Trends Genet 2002;18.
13. Dahl E, Koseki H, Balling R. PAX 2 genes and organogenesis. Bioessays 1997;19:755-756
14. Tong GX, Melamed J, Mansukhani M, et al. PAX 2: a reliable marker for nephrogenic adenoma. Mod Pathol 2006;19:356-363
15. Herlitz LC, Tong GX, Hamele-Bena D, et al. Nephrogenic adenoma identified on urine cytology using PAX 2 immunostaining. Diagn Cytopathol 2008;36:47-49
16. Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX 2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin? Mod Pathol 2007;20:856-866
17. Cormio G, di Vagno G, Meilli GA, et al. Ovarian carcinoma metastatic to the breast. Gynecol Obstet Invest 2001;52:73-74
18. Hajdu SI, Urban JA. Cancer metastatic to the breast. Cancer 1972;29:1691-1696
19. Yamasaki H, Saw D, Zdanowitz J, et al. Ovarian carcinoma metastatis to the breast case report and review of the literature. Am J Surg Pathol 1993;1:193-197
20. Sato T, Muto I, Fushiki M, et al. Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. Breast Cancer 2008;15: 315-320
21. Recine MA, Deavers MT, Middleton LP, et al. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall. Am J Surg Pathol 2004;28:1646-1651
22. Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 2005;29: 1482-1489
23. Striebel JM, Dacic S, Yousem SA. Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma. Am J Surg Pathol 2008;32:426-432
24. Ordoñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol 2006;19:417-428
25. Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology 2003;42:270-279
26. Lae ME, Roche PC, Jin L, et al. Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am J Surg Pathol 2002;26:823-835